| 11.52 0.37 (3.32%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.84 | 1-year : | 16.36 |
| Resists | First : | 12.7 | Second : | 14 |
| Pivot price | 11.62 |
|||
| Supports | First : | 10.6 | Second : | 8.82 |
| MAs | MA(5) : | 11.5 |
MA(20) : | 11.55  |
| MA(100) : | 12.04 |
MA(250) : | 15.59 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28 |
D(3) : | 35.5 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 36.95 | Low : | 7.48 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BHVN ] has closed above bottom band by 35.9%. Bollinger Bands are 63.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.56 - 11.64 | 11.64 - 11.7 |
| Low: | 10.99 - 11.07 | 11.07 - 11.13 |
| Close: | 11.04 - 11.16 | 11.16 - 11.26 |
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Sat, 28 Feb 2026
Biohaven Ltd. (BHVN): A Bull Case Theory - Yahoo Finance
Thu, 26 Feb 2026
BHVN Should I Buy - Intellectia AI
Wed, 25 Feb 2026
Assessing Biohaven (BHVN) Valuation After A Sharp One Year Decline And Recent Three Month Rebound - simplywall.st
Wed, 25 Feb 2026
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tue, 24 Feb 2026
Assessing Biohaven (BHVN) Valuation After A Sharp One Year Decline And Recent Three Month Rebound - Sahm
Tue, 10 Feb 2026
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 133 (M) |
| Shares Float | 85 (M) |
| Held by Insiders | 9.5 (%) |
| Held by Institutions | 89.8 (%) |
| Shares Short | 20,710 (K) |
| Shares Short P.Month | 19,990 (K) |
| EPS | -7.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -106.3 % |
| Return on Equity (ttm) | -522.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.82 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -650 (M) |
| Levered Free Cash Flow | -414 (M) |
| PE Ratio | -1.52 |
| PEG Ratio | 0 |
| Price to Book value | -71.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|